Overview

Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP). The Phase 1 clinical trial investigating this product for the treatment of patients with hepatocellular carcinoma (liver cancer) has been closed to enrollment. The Company continues to develop new cell therapies targeting liver cancer.